Navigation Links
Clinical Trial by Licensee Does Not Meet Primary Endpoint
Date:7/30/2009

PASADENA, Calif., July 30 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today announced its licensee, BioMS Medical Corp., and Eli Lilly and Company reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study. Lilly and BioMS also announced that they would discontinue ongoing clinical trials and review available data.

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, dirucotide, if it reaches the market.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "We are obviously disappointed by the results and look forward to further announcements from BioMS and Lilly regarding their future plans for this approach to treating SPMS."

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, the uncertainties of clinical trial results, AutoImmune's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in AutoImmune's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission in the section entitled "Risk Factors."


'/>"/>
SOURCE AutoImmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Are imaging features of hepatic angiomyolipoma related to its clinical setting?
2. Summa Health System Creates Quick Win With Their Caregiver Community By Implementing Sentillions Clinical Workstation Solution
3. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada
4. HOWARU(R) Protect Clinically Shown to Reduce the Incidence and Severity of Cold and Flu Symptoms in Children
5. Sunshine Heart Provides C-Pulse U.S. Clinical Update
6. QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System
7. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
8. Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009
9. Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study
10. Lutonix, Inc. Announces First Patient Enrollments in Three Separate Clinical Trials
11. Cardiorobotics Closes $11.6M Series A Financing to Advance Clinical Development of Snake Robot for Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... ... SunView Software’s Service Smart Technology has been selected as a finalist for ... year, Pink Elephant recognizes a new product or service developed by an IT services ... opportunity. The award highlights original innovations that were released in 2016, either as a ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... at the National Association of Music Merchants (NAMM) winter trade show, Booth #2876, ... , Etymotic’s ER•4® has long been the gold standard for high-definition, in-ear earphones. ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... as well as Palm Desert, is opening a new office in San Clemente, ... transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling with major ...
(Date:1/17/2017)... ... 17, 2017 , ... Medic-CE , a Career Step ... has released four new continuing education courses as part of its Code3 CME ... online classroom and meet the requirements of the National Continued Competency Program (NCCP), ...
(Date:1/17/2017)... ... 17, 2017 , ... Surgeons from New York’s fastest growing ... on the latest breakthroughs in the prevention, diagnosis and treatment of the most ... eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD and Managing ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Jan. 18, 2017   Seno Medical Instruments, Inc. ... breast cancer through the development of an opto-acoustic (OA/US) ... Miller as SVP of Engineering. Mr. Miller previously ... FUJIFILM SonoSite, with headquarters in Bothell, Washington ... his 30-year career to the development of innovative medical ...
(Date:1/18/2017)... Jan. 18, 2017  Tarix Orphan LLC today announced ... a Rare Pediatric Disease (RPD) designation for the company,s ... Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. There ... is limited to supportive care. "The RPD ... Designation previously granted by the FDA in this indication," ...
(Date:1/18/2017)... January 18, 2017 After the recent ... the use of cannabis both for medical and recreational purposes ... Americans open to the use of cannabis, but the focus ... to Arcview Market Research, the North American legal cannabis market ... the previous year. The research projects sales will grow at ...
Breaking Medicine Technology: